Urolithiasis under atazanavir boosted and tenofovir therapy: a case report.
D'Ettorre
G
G
Zaffiri
L
L
Ceccarelli
G
G
Massetti
A P
AP
Mastroianni
C M
CM
Vullo
V
V
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069446:Atazanavir Sulfate; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009842:Oligopeptides / Q000009:adverse effects* / Q000627:therapeutic use; D063065:Organophosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D019438:Ritonavir / Q000009:adverse effects* / Q000627:therapeutic use; D000068698:Tenofovir; D052878:Urolithiasis / Q000139:chemically induced*; D019562:Viral Load
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D009842:Oligopeptides; D063065:Organophosphonates; D011725:Pyridines; D000069446:Atazanavir Sulfate; D000068698:Tenofovir; D000225:Adenine; D019438:Ritonavir